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Objective: To identify candidate microRNAs (miRNAs) in the serum of patients with clear cell carcinomas
in monitoring disease progression.
Materials and methods: The sera of patients with diagnosed ovarian clear cell carcinoma were collected
from 2009 to 2012. Real-time quantitative polymerase chain reaction (PCR) analysis for 270 miRNAs was
performed. To offset the potential extraction bias, an equal amount of Caenorhabditis elegans cel-miR-238
was added to each serum specimen before miRNA isolation. miRNA expression was analyzed using the
DCt method, with cel-miR-238 as controls.
Results: Twenty-one patients with clear cell carcinoma were included. In the discovery phase on four
pairs of pre- and postoperative sera, 18 differentially expressed miRNAs were selected from 270 miRNAs.
In the validation phase on an independent set of 11 pairs of pre- and postoperative sera, 4 miRNAs (hsa-
miR-130a, hsa-miR-138, hsa-miR-187, and hsa-miR-202) were conﬁrmed to be higher in the preoperative
sera. In the application phase, hsa-miR-130a remained consistent with the different time points in seven
of the 10 patients during clinical follow-up periods. More importantly, in three patients, hsa-miR-130a
levels were elevated in early disease recurrences before CA125 was found to be elevated.
Conclusion: Hsa-miR-130a may be a useful serum biomarker for detecting recurrence of ovarian clear cell
cancer, and warrants further studies.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Epithelial ovarian cancers are one of the most lethal gynecologic
malignancies [1]. Recent discoveries have revealed that epithelial
ovarian cancer is a heterogeneous disease [2e4]. Clear cell carci-
noma is a distinct disease with an increased prevalence reported in
Asian ethnic groups, such as in Taiwan [5] and Japan [6]. Clear celland Gynecology, Chang Gung
yuan, Taiwan.
search Center, Chang Gung
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bstetrics & Gynecology. Publishedcarcinomas are more resistant to the standard chemotherapy of
platinum and paclitaxel than to its serous counterparts in the
advanced stages [7]. Clear cell carcinoma of the ovary has been
reported to be associated with endometriosis [4] and the ARID1A
mutation [8]. However, the tumorigenesis of ovarian clear cell
cancer is still unclear, and clinical management of this disease re-
mains challenging.
MicroRNAs (miRNAs) are noncoding RNA molecules that are
21e25 nucleotides in length, and bind to the 30-untranslated regions
of mRNAs where they inhibit protein translation or promote mRNA
degradation [9]. Many miRNAs are evolutionarily conserved across
plants and animals, indicating that they are involved in a number of
diverse processes. In human cancers, miRNAsmay act as oncomirs or
tumor suppressors [10]. Because distinct miRNA signatures inby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Study design and analytical steps of this study.
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miRNA proﬁles have been used to classify the origin of solid tu-
mors [12]. The roles of miRNAs in cancer tissues, including ovarian
cancer, have been demonstrated in numerous reports [13e15]. In
recent years, circulating miRNAs in serum or plasma have been
proposed as possible biomarkers for speciﬁc cancers [16e19]. In this
study, we aimed to identify candidate miRNAs to be used in moni-
toring the clinical course of clear cell carcinoma.
Materials and methods
Patients
The sera of patients with diagnosed ovarian clear cell carci-
nomas were collected from 2009 to 2013 in our hospital. These
patients included newly diagnosed cases and those who were un-
dergoing follow up. Specimens with obvious hemolysis were
excluded. The Institute Review Board of Chang Gung Memorial
Hospital approved this study (CGMH-IRB #99-0112B and #98-
3644B).
Serum RNA extraction and reverse transcription
Total RNA was isolated using QIAzol reagent (QIAGEN, Taipei,
Taiwan) and miRNeasy Mini Kit (QIAGEN). Brieﬂy, 300 mL of serum
sample was mixed with 700 mL of QIAzol reagent and incubated at
room temperature for 5 minutes. One microliter of 0.05 nM syn-
thetic Caenorhabditis elegans-speciﬁc microRNA cel-miR-238 was
added to each serum specimen as the spike-in control. RNA was
puriﬁed following themanufacture's protocol and eluted in 30 mL of
RNase-free water. Similar procedures, as previously described
[20,21], were performed to convert all miRNAs into corresponding
complementary DNAs (cDNAs) in one reverse transcription (RT)
reaction. Brieﬂy, a 10-mL reaction mixture containing miRNA-
speciﬁc stem-loop RT primers (ﬁnal 0.1 mM each), 500 mM of
deoxy-ribonucleoside triphosphate (dNTP) (ﬁnal), 1 mL of Dithio-
threitol (DTT), 0.5 mL of RNase out, 2 mL of 5  FS buffer, 0.5 mL of
Superscript III (Invitrogen, Carlsbad, CA, USA), and 4.5 mL of total
RNA were used for the RT reaction. The pulsed RT reaction was
performed as follows: 16C for 30 minutes, followed by 50 cycles at
20C for 30 seconds, 42C for 30 seconds, and 50C for 1 second.
The RT product was diluted 20-fold and stored at 80C.
Quantitative RT-(RT-qPCR) polymerase chain reaction
For miRNA quantiﬁcation, 1 mL of diluted RT product was used as
template for a 10-mL polymerase chain reaction (PCR). Brieﬂy,
1  SYBR/TaqMan Master Mix (Applied Biosystem, Foster City, CA,
USA), 200 nM of miRNA-speciﬁc forward primer, and 200 nM of
universal reverse primer were used for each PCR assay. The ther-
mocycles for Q-PCR were: 95C for 10 minutes, followed by 40
cycles of 95C for 15 seconds and 63C for 32 seconds, and a
dissociation stage. All reactions were performed using the ABI
Prism 7900 Fast Real-Time PCR system (Applied Biosystem).
Data analysis
miRNA expression level was analyzed using the DCt method,
with cel-miR-238 as controls. After normalizing the cel-miR-238
level in each sample, expression levels of individual miRNAs were
presented as 39 substrate the value of threshold cycle (Ct) that was
deﬁned as the cycle number when SYBR green/TaqMan signals
appeared. Nonparametric, Wilcoxon tests and ManneWhitney U
tests were performed to identify signiﬁcantly differential expres-
sion of miRNAs between preoperative and postoperative sera.Results
Screening 270 miRNAs in the discovery phase
A total of 25 patients with clear cell carcinoma were included in
this study (Fig. 1). The median age of the patients was 49 years old
(range, 32e59 years). The patients were of International Federation
of Gynecology and Obstetrics (FIGO) stage IC (n ¼ 17), stage IIB
(n¼ 1), IIC (n¼ 1), IIIC (n¼ 2), IV (n¼ 3), and stage X (n¼ 1). Four of
the 25 patients also had endometriosis: two cases in the validation
phase and two in the application phase (Fig. 1). Four pairs of pre-
and postoperative sera were used to select the differentially
expressed miRNAs from 270 miRNAs that have been characterized
in our laboratory. Eighteen miRNAs exhibited changes between
pre- and postoperative sera that were >1.25 fold (Table 1) and were
thus further analyzed in the validation phase.
Identiﬁcation of serum miRNA as potential biomarker
In the validation phase on 11 pairs of sera (Fig. 1), the levels of
four miRNAs, namely hsa-miR-130a, hsa-miR-138, hsa-miR-187,
and hsa-miR-202, were shown to be higher in the preoperative
sera than in the postoperative sera using the SYBR green system
(Fig. 2). The primer sequences of the four miRNAs are summarized
in Table 2. To convert the SYBR green system to the TaqMan system,
we then tested hsa-miR-130a in 12 pairs of preoperative and
postoperative sera. A drop in the postoperative hsa-miR-130a was
conﬁrmed in nine pairs of sera.
Hsa-miR-130a may be useful for early detection of disease
recurrence
In the application phase (Fig. 1), we measured hsa-miR-130a in
serum specimens collected from four patients with cancer recur-
rence (Fig. 3A) and six patients without recurrences (Fig. 3B). The
changes in hsa-miR-130a were consistent with disease status in
seven patients: increasing trends of hsa-miR-130a were seen in all
four patients with recurrent cancer (Fig. 3A), and decreasing trends
of hsa-miR-130a in three (50%) out of six patients without recur-
rence (Fig. 3B). CA125 levels were also measured in all of the
specimens. Of note, all of the six patients without recurrent cancer
exhibited decreasing trends of serum CA125 levels (Fig. 3B).
The most challenging, but clinically important, task was to
identify the cases in which cancer had either already recurred or
will recur. In the four patients with cancer recurrence, an increase
in CA125 identiﬁed only one case (25%), whereas hsa-miR-130a
Table 1
MicroRNAs signiﬁcantly upregulated in the serum of clear cell carcinomas of the
ovary (fold change >1.25 and p < 0.05).
MicroRNA Chromosome Fold change ManneWhitney
hsa-miR-202 Chr10_15 2.33 0.03
hsa-miR-365 Chr16_03 2.11 0.03
hsa-miR-1 Chr20_08 2.09 0.03
hsa-miR-130a Chr11_06 2.07 0.03
hsa-miR-363 ChrX_13 1.93 0.03
hsa-miR-187 Chr18_02 1.91 0.03
hsa-miR-200b Chr1_01 1.89 0.03
hsa-miR-181a Chr1_25 1.68 0.03
hsa-miR-138 Chr3_05 1.64 0.03
hsa-miR-29b-1* Chr7_16 1.55 0.03
hsa-miR-29b Chr7_16 1.54 0.03
hsa-miR-519d Chr19_18 1.53 0.03
hsa-miR-195 Chr17_03 1.51 0.03
hsa-miR-25* Chr7_10 1.43 0.03
hsa-miR-760 Chr1_10 1.39 0.03
hsa-miR-565 Chr3_07 1.38 0.03
hsa-miR-196a* Chr17_15 1.36 0.03
hsa-miR-125b Chr11_14 1.27 0.03
Asterisks indicate the historical nomenclature, and the current names are as follows:
miR-29b-1* = miR-29b-1-5p; miR-25* = miR-25-5p; miR-196a* = miR-196a-3p.
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tantly, three cases showed increasing trends of serum hsa-miR-
130a even when CA125 levels remained within normal range
(35 U/mL; Cases 1e3. Fig. 3A).
The clinical histories of Cases 1e3 are summarized as follows
(Fig. 3A). For Patient 1 (51 years old, stage IIB), CA125 levels were
within normal range in the two sera collected 3 months apart.
However, recurrent cancer in the left pouch of Douglas extending
to the left vaginal stump was conﬁrmed on computed tomography
(CT) 1 month after the ﬁrst time point. Patient 2 (32 years old,
stage IC) underwent the third surgery for multiple peritoneal
metastases. CA125 did not increase 6 weeks before the surgery,
but hsa-miR-130a was increased between the two time points. ForFig. 2. Four circulating miRNAs were signiﬁcantly higher in pre- than inPatient 3 (42 years old, stage IC), tumor metastases were sus-
pected on CT images 3 months after a cytoreductive surgery, but
the serum CA125 levels decreased from 9.6 U/mL to 7.1 U/mL in
the following 4 months. Advanced intraabdominal cancer re-
currences in the mesentery, left paracolic gutter, and subphrenic
and hepatorenal space were conﬁrmed intraoperatively 10 months
later. Collectively, these results indicate that an elevation of hsa-
miR-130a may detect early disease recurrence before an increase
in CA125 is seen.Discussion
Clinical values of circulating miRNAs in blood have been hy-
pothesized to be applicable as a tumor marker in various cancers
[19,22e28], and circulating miRNAs have been reported in patients
with ovarian cancer [18,29e33]. Those studies were primarily
focused on the identiﬁcation ofmiRNAs that could be used to follow
the serous type of ovarian cancer. To our knowledge, this study is
the ﬁrst report of analyzing serum miRNA panels in patients with
ovarian clear cell carcinomas. Our systematic approach has led to
the ﬁnding that hsa-miR-130a may be a useful marker for early
detection of disease recurrence.
CA125 assessment is currently the standard of care in making
diagnosis, following response to treatment, and predicting prog-
nosis in ovarian cancer [34]. The sensitivity of CA125 is 85% using
the cut-off of 35 U/mL [35]. In our previous report, 12% of invasive
ovarian cancers in 403 cases collected between 2000 and 2005
were below normal range [36]. For these patients, biomarkers other
than serum CA125 are needed.
Epidemiological and molecular studies have shown strong as-
sociations between ovarian clear cell carcinoma and endometri-
osis [37,38]. In this study, four of the 25 patients also had
endometriosis in the ﬁnal pathology. The plasma miRNAs that
have been associated with endometriosis include miR-17-5p, miR-
20a, and miR-22 [39]. MiR-199a, miR-122, miR-145, and miR-542-
3p have also been proposed to be potential biomarkers forpostoperative sera. postop ¼ postoperative; preop ¼ preoperative.
Table 2






























PCR ¼ polymerase chain reaction; RT ¼ reverse transcription.
Fig. 3. The changes in hsa-miR-130a in 10 patients with ovarian clear cell cancer. (A) During
imaging results with computed tomography and/or histological results after operation. (B) D
Time zero indicates the date of operation. Serum specimens at the ﬁrst time point were coll
the value of serum CA125 (U/mL).
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ovarian cancer (endometrioid and clear cell carcinoma of the
ovary) also displayed a panel of 10 differentially expressedmiRNAs
[41]. None of these published miRNAs include miR-130a. It re-
mains unclear whether miR-130a can be used as another serum
marker for endometriosis.
In the literature, hsa-miR-130a has been mainly regarded as an
oncomir. Hsa-miR-130a was reported to downregulate Smad4 and
suppress the TGF-b1-inducedgrowth inhibition in granulocytic cells
[42]. Hsa-miR-130a may activate Wnt/b-catenin signaling and in-
crease drug resistance in hepatocellular carcinoma cells by inhibit-
ing the RUNX3 pathway [43]. By targeting ATG2B and DICER1, hsa-
miR-130a may modulate autophagy as cell survival programs in
chronic lymphocytic leukemia cells [44]. In ovarian cancer cells, hsa-
miR-130a may be associated with the PI3K/Akt/PTEN/mTOR
signalingpathways andplaya role in cisplatin resistance [45]. On the
other hand, hsa-miR-130a may also be a tumor suppressor. For
instance, hsa-miR-130a was shown to induce tumor necrosis factor
(TNF)-related apoptosis-inducing ligand (TRAIL) sensitivity in non-
small cell lung cancer cells through the c-Jun-mediatedthe follow-up period, four patients had cancer recurrences, which were conﬁrmed by
uring the follow-up period, six patients did not have cancer recurrences after operation.
ected 1 day after operation. The number shown in the parenthesis at each time point is
A. Chao et al. / Taiwanese Journal of Obstetrics & Gynecology 53 (2014) 536e541540downregulation of miR-221 and miR-222 [46]. Furthermore, serum
miR-130a has been recently used as a biomarker for multiple
myeloma [47] and metabolic syndrome [48].
Correlations of miRNAs between tissue and serum are some-
times inconsistent [23,41]. Serum levels of miR-200c could predict
the response to chemotherapy and the prognosis of patients with
esophageal cancer who received neoadjuvant chemotherapy, but
the tissue levels of hsa-miR-200c in these patients did not correlate
with the serum level [23]. The results of this study indicated that
hsa-miR-187 was highly expressed in preoperative sera (Fig. 2), in
agreement with our previous report that hsa-miR-187 was higher
in ovarian cancer tissues than in benign tumors [15]. However, hsa-
miR-187 failed to serve as a predictor of early recurrence according
to the stringent criteria of this study. The mechanism of how
cancer-expressed miRNAs enter the circulation warrants further
investigation.
Microarray analyses of gene expression have been widely used
in cancer tissues [49,50]. miRNA arrays have been used for the
purpose of screening candidate miRNAs in ovarian tumors and
other cancers [18,19,23,29,32]. In addition, RT-qPCR assays using
Taqman [22,24,30,31] or SYBR [26,33] probes were alternative
platforms. SYBR RT-qPCR/TaqMan assays protocols have been
applied in our previous studies [20,21] and the present investiga-
tion. Selection of miRNA reference controls for normalization is
required to avoid system bias in such experiments. C. elegans
miRNAs including cel-miR-238 [23,32], as in this study, and cel-
miR-43, cel-miR-54, and cel-miR-238 are often adopted as spike-
in controls to reduce technical variation in the experiments [19].
However, this strategy does not exclude the intrinsic biological
variations among different study participants [19]. These limita-
tions were also seen in the commonly used miR-16 [19,22,33] and
RNU6B [23,24] as endogenous controls. Therefore, inconsistencies
may still arise from the use of reference controls even within the
same tumor type.
miRNAs are resistant to endogenous RNase activity and show
high stability in plasma or serum [16], enabling miRNAs to hold
great promises as potential biomarkers. However, there are two
problems when utilizing serum or plasma in detecting miRNA
levels. First, blood cells contribute partly to the expression of
miRNAs within clinical contexts [51,52]. Pritchard et al [51]
analyzed 79 circulating miRNA biomarkers for solid tumors and
found that myeloid (e.g., hsa-miR-223, hsa-miR-197, hsa-miR-574-
3p, and hsa-let-7a) and lymphoid (e.g., hsa-miR-150) blood cells
were tightly correlated with corresponding white blood cell counts
[51]. Thus, hemolysis can interfere with plasma miRNA levels by up
to 50-fold. We excluded hemolysis-affecting miRNAs from our 18-
miRNA panel (unpublished data) and avoided hemolyzed speci-
mens that could be identiﬁed by the naked eye. However, an
objective measure to determine the acceptable level of hemolysis
while assessing the circulating miRNAs is lacking. Currently, our
understanding of blood components' contribution to the levels of
circulating miRNAs may remain incomplete.
Second, the preanalytical and analytical sources of variation in
the measurement of circulating miRNAs levels are also likely to
have an impact on the results [19,51,52]. If plasma specimens are to
be analyzed, sample collection using anticoagulants either with
EDTA or heparin should remain consistent throughout the study.
Robust methods of RNA extraction and data normalization are
critical in the reproducibility and reliability of circulating miRNA
assays.
In conclusion, validation of miRNAs as candidate biomarkers is
possible if the sources of variation that inﬂuence plasma or serum
miRNA levels are minimized, and if an appropriate reference of
normalization can be identiﬁed. A larger sample size is necessary to
conﬁrm hsa-miR-130a for its applicability as a potential biomarkerin early detection, treatment monitoring, and predicting patient
outcome in ovarian cancer.
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